Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Pralatrexate (Primary) ; Romidepsin (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results from NCT01998035 and NCT01947140 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 06 Mar 2019 Planned End Date changed from 1 Jan 2019 to 1 Jul 2020.
- 06 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.